1 40 10 Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Pages 1613–1618 Issue 10 Volume 5 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Anthocyanin-rich black currant extract suppresses the growth of human hepatocellular carcinoma cells. Publisher An entity responsible for making the resource available Natural product communications Date A point or period of time associated with an event in the lifecycle of the resource 2010 2010-10 Subject The topic of the resource Humans; Cell Proliferation/drug effects; Fruit/chemistry; *Phytotherapy; Plant Extracts/pharmacology/therapeutic use; Hep G2 Cells; Antioxidants/*therapeutic use; *Ribes/chemistry; Liver Neoplasms/*prevention & control; Carcinoma; Drug Evaluation; Preclinical; Antineoplastic Agents; Hepatocellular/*prevention & control; Phytogenic/analysis Creator An entity primarily responsible for making the resource Bishayee Anupam; Haznagy-Radnai Erzsebet; Mbimba Thomas; Sipos Peter; Morazzoni Paolo; Darvesh Altaf S; Bhatia Deepak; Hohmann Judit Description An account of the resource Dietary antioxidants, such as anthocyanins, are helpful in the prevention and control of various diseases by counteracting the imbalance of oxidative and antioxidative factors in the living systems. Black currant (Ribes nigrum L., Grossulariaceae) is known to contain high amounts of anthocyanins (250 mg/100 g fresh fruit). Black currant fruits have been used in Asian and European traditional medicine for the treatment of a variety of diseases. Black currant extract has recently been found to be the second most effective amongst nine different berry extracts studied for their free radical scavenging activity. Constituents present in black currant juice have been found to exert a number of health-promoting effects, including immunomodulatory, antimicrobial and antiinflammatory actions, inhibition of low-density lipoprotein, and reduction of cardiovascular diseases. Although antioxidant and antiinflammatory effects of black currant juice could be of value in preventing and treating oxidative stress- and inflammation-driven cancers, no experimental evidence is available to now. The objective of the present study was to evaluate the potential antiproliferative effects of black currant fruit skin extract against HepG2 human liver cancer cells. The aqueous extract yielded an anthocyanin-rich fraction with cyanidin-3-O-rutinoside as one of the major anthocyanins. This fraction exhibited a potent cytotoxic effect on HepG2 cells and this effect was more pronounced than that of delphinidin and cyanidin, two major aglycones of anthocyanins present in black currant. Our results indicate, for the first time, that black currant skin containing an anthocyanin-rich fraction inhibits the proliferation of liver cancer cells, possibly due to additive as well as synergistic effects. This product could be useful in the prevention and treatment of human hepatocellular carcinoma. Rights Information about rights held in and over the resource Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s). *Phytotherapy *Ribes/chemistry 2010 Antineoplastic Agents Antioxidants/*therapeutic use Bhatia Deepak Bishayee Anupam Carcinoma Cell Proliferation/drug effects Darvesh Altaf S Department of Pharmaceutical Sciences Drug Evaluation Fruit/chemistry Haznagy-Radnai Erzsebet Hep G2 Cells Hepatocellular/*prevention & control Hohmann Judit Humans Liver Neoplasms/*prevention & control Mbimba Thomas Morazzoni Paolo Natural product communications NEOMED College of Pharmacy Phytogenic/analysis Plant Extracts/pharmacology/therapeutic use Preclinical Sipos Peter Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. URL Address <a href="http://doi.org/10.4155/fmc.12.72" target="_blank" rel="noreferrer noopener">http://doi.org/10.4155/fmc.12.72</a> Pages 1307–1333 Issue 10 Volume 4 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Noncanonical mechanisms to regulate nuclear receptor signaling. Publisher An entity responsible for making the resource available Future medicinal chemistry Date A point or period of time associated with an event in the lifecycle of the resource 2012 2012-06 Subject The topic of the resource Humans; Protein Binding; MicroRNAs/metabolism; Signal Transduction/drug effects; Ligands; DNA/metabolism; Peptides/chemistry/pharmacology; Small Molecule Libraries/chemistry/pharmacology; Receptors; Drug Evaluation; Preclinical; Cytoplasmic and Nuclear/antagonists & inhibitors/*metabolism Creator An entity primarily responsible for making the resource Sadana Prabodh Description An account of the resource Nuclear receptor (NR)-targeted therapies comprise a large class of clinically employed drugs. A number of drugs currently being used against this protein class were designed as structural analogs of the endogenous ligand of these receptors. In recent years, there has been significant interest in developing newer strategies to target NRs, especially those that rely on mechanistic pathways of NR function. Prominent among these are noncanonical means of targeting NRs, which include selective NR modulation, NR coactivator interaction inhibition, inhibition of NR DNA binding, modulation of NR cellular localization, modulation of NR ligand biosynthesis and downregulation of NR levels in target tissues. This article reviews each of these promising emerging strategies for NR drug development and highlights some of most significant successes achieved in using them. Identifier An unambiguous reference to the resource within a given context <a href="http://doi.org/10.4155/fmc.12.72" target="_blank" rel="noreferrer noopener">10.4155/fmc.12.72</a> Rights Information about rights held in and over the resource Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s). 2012 Cytoplasmic and Nuclear/antagonists & inhibitors/*metabolism Department of Pharmaceutical Sciences Department of Pharmacy Practice DNA/metabolism Drug Evaluation Future medicinal chemistry Humans Ligands MicroRNAs/metabolism NEOMED College of Graduate Studies NEOMED College of Pharmacy Peptides/chemistry/pharmacology Preclinical Protein Binding Receptors Sadana Prabodh Signal Transduction/drug effects Small Molecule Libraries/chemistry/pharmacology Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. URL Address <a href="http://doi.org/10.2165/11590190-000000000-00000" target="_blank" rel="noreferrer noopener">http://doi.org/10.2165/11590190-000000000-00000</a> Pages 765–781 Issue 9 Volume 25 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Role of serotonin in Alzheimer's disease: a new therapeutic target? Publisher An entity responsible for making the resource available CNS Drugs Date A point or period of time associated with an event in the lifecycle of the resource 2011 2011-09 Subject The topic of the resource Humans; Animals; Serotonin/*metabolism; Clinical Trials as Topic; Alzheimer Disease/*drug therapy/*metabolism; Serotonin/*pharmacology/*therapeutic use; Clinical Trials; Receptors; Drug Evaluation; Preclinical; Alzheimer's Disease – Drug Therapy; Alzheimer's Disease – Metabolism; Cell Surface – Metabolism; Serotonin – Pharmacodynamics; Serotonin – Therapeutic Use Creator An entity primarily responsible for making the resource Geldenhuys Werner J; Van der Schyf Cornelis J Description An account of the resource Mounting evidence accumulated over the past few years indicates that the neurotransmitter serotonin plays a significant role in cognition. As a drug target, serotonin receptors have received notable attention due in particular to the role of several serotonin-receptor subclasses in cognition and memory. The intimate anatomical and neurochemical association of the serotonergic system with brain areas that regulate memory and learning has directed current drug discovery programmes to focus on this system as a major therapeutic drug target. Thus far, none of these programmes has yielded unambiguous data that suggest that any of the new drug entities possesses disease-modifying properties, and significantly more research in this promising area of investigation is required. Compounds are currently being investigated for activity against serotonin 5-HT(1), 5-HT(4) and Identifier An unambiguous reference to the resource within a given context <a href="http://doi.org/10.2165/11590190-000000000-00000" target="_blank" rel="noreferrer noopener">10.2165/11590190-000000000-00000</a> Rights Information about rights held in and over the resource Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s). 2011 Alzheimer Disease/*drug therapy/*metabolism Alzheimer's Disease – Drug Therapy Alzheimer's Disease – Metabolism Animals Cell Surface – Metabolism Clinical Trials Clinical Trials as Topic CNS drugs Drug Evaluation Geldenhuys Werner J Humans Preclinical Receptors Serotonin – Pharmacodynamics Serotonin – Therapeutic Use Serotonin/*metabolism Serotonin/*pharmacology/*therapeutic use Van der Schyf Cornelis J Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. URL Address <a href="http://doi.org/10.1517/13543784.2012.693479" target="_blank" rel="noreferrer noopener">http://doi.org/10.1517/13543784.2012.693479</a> Pages 1123–1140 Issue 8 Volume 21 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Curcumin and neurodegenerative diseases: a perspective. Publisher An entity responsible for making the resource available Expert opinion on investigational drugs Date A point or period of time associated with an event in the lifecycle of the resource 2012 2012-08 Subject The topic of the resource Humans; Animals; Oxidative Stress/drug effects; Neurodegenerative Diseases/*drug therapy/metabolism; Curcumin/adverse effects/pharmacokinetics/*pharmacology/*therapeutic use; Neuroprotective Agents/adverse effects/pharmacokinetics/*pharmacology/*therapeutic use; Drug Evaluation; Preclinical Creator An entity primarily responsible for making the resource Darvesh Altaf S; Carroll Richard T; Bishayee Anupam; Novotny Nicholas A; Geldenhuys Werner J; Van der Schyf Cornelis J Description An account of the resource INTRODUCTION: Curcumin, a dietary polyphenol found in the curry spice turmeric, possesses potent antioxidant and anti-inflammatory properties and an ability to modulate multiple targets implicated in the pathogenesis of chronic illness. Curcumin has shown therapeutic potential for neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD). AREAS COVERED: This article highlights the background and epidemiological evidence of curcumin's health benefits and its pharmacodynamic and pharmacokinetic profile. Curcumin's ability to counteract oxidative stress and inflammation and its capacity to modulate several molecular targets is reviewed. We highlight the neuroprotective properties of curcumin including pre-clinical evidence for its pharmacological effects in experimental models of AD and PD. The bioavailability and safety of curcumin, the development of semi-synthetic curcuminoids as well as novel formulations of curcumin are addressed. EXPERT OPINION: Curcumin possesses therapeutic potential in the amelioration of a host of neurodegenerative ailments as evidenced by its antioxidant, anti-inflammatory and anti-protein aggregation effects. However, issues such as limited bioavailability and a paucity of clinical studies examining its therapeutic effectiveness in illnesses such as AD and PD currently limit its therapeutic outreach. Considerable effort will be required to adapt curcumin as a neuroprotective agent to be used in the treatment of AD, PD and other neurodegenerative diseases. Identifier An unambiguous reference to the resource within a given context <a href="http://doi.org/10.1517/13543784.2012.693479" target="_blank" rel="noreferrer noopener">10.1517/13543784.2012.693479</a> Rights Information about rights held in and over the resource Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s). 2012 Animals Bishayee Anupam Carroll Richard T Curcumin/adverse effects/pharmacokinetics/*pharmacology/*therapeutic use Darvesh Altaf S Department of Pharmaceutical Sciences Drug Evaluation Expert opinion on investigational drugs Geldenhuys Werner J Humans NEOMED College of Pharmacy Neurodegenerative Diseases/*drug therapy/metabolism Neuroprotective Agents/adverse effects/pharmacokinetics/*pharmacology/*therapeutic use Novotny Nicholas A Oxidative Stress/drug effects Preclinical Van der Schyf Cornelis J Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. URL Address <a href="http://doi.org/10.1371/journal.pone.0122189" target="_blank" rel="noreferrer noopener">http://doi.org/10.1371/journal.pone.0122189</a> Pages e0122189–e0122189 Issue 4 Volume 10 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Propofol causes vasodilation in vivo via TRPA1 ion channels: role of nitric oxide and BKCa channels. Publisher An entity responsible for making the resource available PloS one Date A point or period of time associated with an event in the lifecycle of the resource 2015 1905-07 Subject The topic of the resource Female; Male; Animals; Mice; Signal Transduction; TRPA1 Cation Channel; Arterial Pressure/drug effects; Vasodilator Agents/*pharmacology; Propofol/*pharmacology; Transient Receptor Potential Channels/genetics/*metabolism; Large-Conductance Calcium-Activated Potassium Channel alpha Subunits/*physiology; Nitric Oxide/*physiology; TRPV Cation Channels/genetics/metabolism; Inbred C57BL; Knockout; Drug Evaluation; Preclinical Creator An entity primarily responsible for making the resource Sinha Sayantani; Sinharoy Pritam; Bratz Ian N; Damron Derek S Description An account of the resource BACKGROUND: Transient receptor potential (TRP) ion channels of the A1 (TRPA1) and V1 (TRPV1) subtypes are key regulators of vasomotor tone. Propofol is an intravenous anesthetic known to cause vasorelaxation. Our objectives were to examine the extent to which TRPA1 and/or TRPV1 ion channels mediate propofol-induced depressor responses in vivo and to delineate the signaling pathway(s) involved. METHODS: Mice were subjected to surgery under 1.5-2.5% sevoflurane gas with supplemental oxygen. After a stable baseline in mean arterial pressure (MAP) was achieved propofol (2.5, 5.0, 10.0 mg/kg/min) was administered to assess the hemodynamic actions of the intravenous anesthetic. The effect of nitric oxide synthase (NOS) inhibition with L-NAME and/or calcium-gated K+ channel (BKCa) inhibition with Penetrim A (Pen A), alone and in combination, on propofol-induced decreases in mean arterial pressure were assessed in control C57Bl/6J, TRPA1-/-, TRPV1-/- and double-knockout mice (TRPAV-/-). RESULTS: Propofol decreased MAP in control mice and this effect was markedly attenuated in Identifier An unambiguous reference to the resource within a given context <a href="http://doi.org/10.1371/journal.pone.0122189" target="_blank" rel="noreferrer noopener">10.1371/journal.pone.0122189</a> Rights Information about rights held in and over the resource Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s). 2015 Animals Arterial Pressure/drug effects Bratz Ian N Damron Derek S Drug Evaluation Female Inbred C57BL Knockout Large-Conductance Calcium-Activated Potassium Channel alpha Subunits/*physiology Male Mice Nitric Oxide/*physiology PloS one Preclinical Propofol/*pharmacology Signal Transduction Sinha Sayantani Sinharoy Pritam Transient Receptor Potential Channels/genetics/*metabolism TRPA1 Cation Channel TRPV Cation Channels/genetics/metabolism Vasodilator Agents/*pharmacology Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. URL Address <a href="http://doi.org/10.1080/03639045.2018.1483381" target="_blank" rel="noreferrer noopener">http://doi.org/10.1080/03639045.2018.1483381</a> Pages 1583–1590 Issue 10 Volume 44 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Preparation of emulsifying wax/glyceryl monooleate nanoparticles and evaluation as a delivery system for repurposing simvastatin in bone regeneration. Publisher An entity responsible for making the resource available Drug development and industrial pharmacy Date A point or period of time associated with an event in the lifecycle of the resource 2018 2018-10 Subject The topic of the resource Animals; bone; Bone Regeneration/*drug effects/physiology; drug delivery; Drug Delivery Systems/*methods; Drug Evaluation; Drug Repositioning/methods; Emulsifying Agents/administration & dosage/*chemical synthesis; Glycerides/administration & dosage/*chemical synthesis; Mice; nanoemulsions; nanoparticles; Nanoparticles/administration & dosage/*chemistry; osteoblasts; Osteoblasts/drug effects/physiology; Osteoclasts; Preclinical/methods; RAW 264.7 Cells; Simvastatin/administration & dosage/*chemical synthesis; Waxes/chemical synthesis/pharmacology Creator An entity primarily responsible for making the resource Eskinazi-Budge Aaron; Manickavasagam Dharani; Czech Tori; Novak Kimberly; Kunzler James; Oyewumi Moses O Description An account of the resource Simvastatin (Sim) is a widely known drug in the treatment of hyperlipidemia, which has attracted so much attention in bone regeneration due to its potential osteoanabolic effect. However, repurposing of Sim in bone regeneration will require suitable delivery systems that can negate undesirable off-target/side effects. In this study, we have investigated a new lipid nanoparticle (NP) platform that was fabricated using a binary blend of emulsifying wax (Ewax) and glyceryl monooleate (GMO). Using the binary matrix materials, NPs loaded with Sim (0-500 microg/mL) were prepared and showed an average particle size of about 150 nm. NP size stability was dependent on Sim concentration loaded in NPs. The suitability of NPs prepared with the binary matrix materials in Sim delivery for potential application in bone regeneration was supported by biocompatibility in pre-osteoclastic and pre-osteoblastic cells. Additional data demonstrated that biofunctional Sim was released from NPs that facilitated differentiation of osteoblasts (cells that form bones) while inhibiting differentiation of osteoclasts (cells that resorb bones). The overall work demonstrated the preparation of NPs from Ewax/GMO blends and characterization to ascertain potential suitability in Sim delivery for bone regeneration. Additional studies on osteoblast and osteoclast functions are warranted to fully evaluate the efficacy of Sim-loaded Ewax/GMO NPs using in-vitro and in-vivo approaches. Identifier An unambiguous reference to the resource within a given context <a href="http://doi.org/10.1080/03639045.2018.1483381" target="_blank" rel="noreferrer noopener">10.1080/03639045.2018.1483381</a> Rights Information about rights held in and over the resource Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s). 2018 Animals Bone Bone Regeneration/*drug effects/physiology Czech Tori Department of Pharmaceutical Sciences Drug delivery Drug Delivery Systems/*methods Drug development and industrial pharmacy Drug Evaluation Drug Repositioning/methods Emulsifying Agents/administration & dosage/*chemical synthesis Eskinazi-Budge Aaron Glycerides/administration & dosage/*chemical synthesis Kunzler James Manickavasagam Dharani Mice nanoemulsions Nanoparticles Nanoparticles/administration & dosage/*chemistry NEOMED College of Pharmacy Novak Kimberly Osteoblasts Osteoblasts/drug effects/physiology Osteoclasts Oyewumi Moses O Preclinical/methods RAW 264.7 Cells Simvastatin/administration & dosage/*chemical synthesis Waxes/chemical synthesis/pharmacology Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. URL Address <a href="http://doi.org/10.1016/s0091-3057(96)00301-2" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/s0091-3057(96)00301-2</a> Pages 457–463 Issue 3 Volume 56 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Discriminative characteristics of high and low cocaine administration: effect of other psychostimulants. Publisher An entity responsible for making the resource available Pharmacology, biochemistry, and behavior Date A point or period of time associated with an event in the lifecycle of the resource 1997 1997-03 Subject The topic of the resource Amphetamine/pharmacology; Animals; Central Nervous System Stimulants/pharmacology; Cocaine/*pharmacology; Conditioning; Discrimination Learning/*drug effects; Dopamine Agents/*pharmacology; Dose-Response Relationship; Drug; Drug Evaluation; Generalization; Male; Methamphetamine/pharmacology; Operant/*drug effects; Preclinical; Propiophenones/pharmacology; Psychotropic Drugs/*pharmacology; Rats; Response/*drug effects Creator An entity primarily responsible for making the resource Schechter M D Description An account of the resource Two groups of N/Nih male rats were trained to discriminate saline vehicle from either 2.0 mg/kg (n = 10) or 10.0 mg/kg (n = 10) cocaine in a food-motivated, two-lever operant paradigm. The rats trained at the low-dose cocaine took a significantly longer training period to reach criterion performance than did the high-dose cocaine group. In addition, the ED50 value for the 2.0 mg/kg cocaine-trained animals (0.465 mg/kg) was significantly lower than the ED50 value (2.105 mg/kg) for those animals trained at the 10.0 mg/kg dose of cocaine. This correlation of ED50 values for stimulus generalization decreasing with reduction in training dose was in contrast to the time-course of the two groups when tested from 15 to 240 min post-injection; this experimentation indicated that there was a non-significant difference in half-life for the 2.0 mg/kg (t1/2: 97.1 min) vs. that of the 10.0 mg/kg cocaine-trained group (t1/2: 83.4 min). Generalization tests with other purportedly dopaminergically-active drugs of abuse including 0.05-0.8 mg/kg d-amphetamine, 0.125-1.5 mg/kg methamphetamine and 0.125-1.0 mg/kg methcathinone indicated that the highest doses of each produced generalization and, with the exception of methcathinone, the ED50 values were significantly lower in the low-cocaine trained group. The stimulus properties of cocaine, as they generalize to amphetamine, methamphetamine and methcathinone, can be explained by effects upon central dopaminergic neurons and may be qualitatively different in low-and high-dose trained rats. Identifier An unambiguous reference to the resource within a given context <a href="http://doi.org/10.1016/s0091-3057(96)00301-2" target="_blank" rel="noreferrer noopener">10.1016/s0091-3057(96)00301-2</a> Rights Information about rights held in and over the resource Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s). 1997 Amphetamine/pharmacology Animals Central Nervous System Stimulants/pharmacology Cocaine/*pharmacology Conditioning Discrimination Learning/*drug effects Dopamine Agents/*pharmacology Dose-Response Relationship Drug Drug Evaluation Generalization Male Methamphetamine/pharmacology Operant/*drug effects Pharmacology, biochemistry, and behavior Preclinical Propiophenones/pharmacology Psychotropic Drugs/*pharmacology Rats Response/*drug effects Schechter M D Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. URL Address <a href="http://doi.org/10.1016/s0014-2999(97)85404-0" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/s0014-2999(97)85404-0</a> Pages 113–118 Issue 2 Volume 326 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Discrete versus cumulative dosing in dose-response discrimination studies. Publisher An entity responsible for making the resource available European journal of pharmacology Date A point or period of time associated with an event in the lifecycle of the resource 1997 1997-05 Subject The topic of the resource 4-methylenedioxyamphetamine/*pharmacology; Animals; Chemical; Cocaine/*pharmacology; Discrimination Learning/*drug effects; Dose-Response Relationship; Drug; Drug Administration Schedule; Drug Evaluation; Male; N-Methyl-3; Preclinical; Rats; Sprague-Dawley; Stimulation Creator An entity primarily responsible for making the resource Schechter M D Description An account of the resource This study describes the results of a 'side-by-side' comparison of two measurement techniques and two dosing regimens in a discrimination study using rats trained to either 10 mg/kg cocaine or 2 mg/kg 3,4-methylenedioxymethamphetamine (MDMA). The measurements employed were either quantal or quantitative; the former an all-or-none correct lever selection measure and the latter a measure of all responses made at the time that the criterion for selection was met. The dosing regimens were either a discrete single injection of lower doses than used in training or a cumulative dose administration sequence, in an ascending order, during one session on two separate occasions. Results indicate that the cumulative dose-response relationships, as indicated by both the slope of the curve or the generated ED50 value, for the discrete and cumulative dose response curves do not significantly differ. In addition, both the quantal and quantitative measurements yield almost identical ED50 values, thus allowing for accurate comparability of drug-discrimination data using different techniques. The present experimentation employed two drugs known to produce heightened response rates which would not allow for behavioral suppression at the highest doses used either in discrete or cumulative regimens. The pharmacokinetics of the two drugs employed in the discrimination tests are considered and discussed in light of the advantages and disadvantages of each of the two methods employed. Identifier An unambiguous reference to the resource within a given context <a href="http://doi.org/10.1016/s0014-2999(97)85404-0" target="_blank" rel="noreferrer noopener">10.1016/s0014-2999(97)85404-0</a> Rights Information about rights held in and over the resource Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s). 1997 4-methylenedioxyamphetamine/*pharmacology Animals Chemical Cocaine/*pharmacology Discrimination Learning/*drug effects Dose-Response Relationship Drug Drug Administration Schedule Drug Evaluation European journal of pharmacology Male N-Methyl-3 Preclinical Rats Schechter M D Sprague-Dawley Stimulation Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. URL Address <a href="http://doi.org/10.1016/j.antiviral.2005.06.008" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.antiviral.2005.06.008</a> Pages 155–162 Issue 3 Volume 67 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Effect of resveratrol on herpes simplex virus vaginal infection in the mouse. Publisher An entity responsible for making the resource available Antiviral research Date A point or period of time associated with an event in the lifecycle of the resource 2005 2005-09 Subject The topic of the resource Animals; Antiviral Agents/administration & dosage/pharmacology/*therapeutic use; Drug Evaluation; Female; Herpes Genitalis/*drug therapy/pathology/virology; Herpesvirus 1; Herpesvirus 2; Human/*drug effects/physiology; Human/drug effects/isolation & purification/physiology; Mice; Placebos; Preclinical; Resveratrol; Stilbenes/administration & dosage/pharmacology/*therapeutic use; Survival Analysis; Vaginal Diseases/*drug therapy/virology; Viral Plaque Assay; Virus Replication/drug effects Creator An entity primarily responsible for making the resource Docherty John J; Fu Ming Ming; Hah Jennifer M; Sweet Thomas J; Faith Seth A; Booth Tristan Description An account of the resource Resveratrol (3,5,4'-trihydroxystilbene) is a natural component of certain foods, such as grapes, that, when topically applied, has been shown to limit HSV-1 lesion formation in the skin of mice [Antiviral Res. 61:19-26, 2004]. To determine if it is active on genital HSV infection, the vagina of mice were infected with HSV-2 or HSV-1 and treated with a cream formulation of resveratrol. Mice were evaluated daily for extravaginal disease and vaginal swabs were taken regularly and assayed for infectious virus. Initial studies demonstrated that 19% resveratrol cream administered intravaginally five times a day for 5 days beginning 1h after infection significantly reduced HSV-2 replication beginning on day 1 of infection and prevented extravaginal disease when compared to animals treated with placebo. When resveratrol was tested at a concentration of 6.25% and 12.5% administered five times a day, 6.25% limited virus replication only on day 1 and delayed development of extravaginal disease by 1 day. However, 12.5% resveratrol inhibited HSV-2 replication beginning on day 1 and abolished extravaginal disease. If the number of applications per day was reduced to three for 5 days, 12.5% resveratrol inhibited HSV-2 replication only on day 1, while 19% resveratrol inhibited it throughout the 9-day assay period. When the animals with three treatments per day were examined for extravaginal disease, it was found that 12.5% resveratrol was ineffective when compared to placebo, while animals treated with 19% resveratrol did not exhibit extravaginal disease. When treatment was delayed 6h, 12.5% resveratrol did not inhibit HSV-2 replication or extravaginal lesion formation, but 19% resveratrol did. When resveratrol was used to treat vaginal HSV-1 infection, it was found that 12.5% resveratrol did not limit replication or prevent extravaginal lesion formation. In contrast, 19% resveratrol did significantly limit vaginal HSV-1 replication and reduced extravaginal lesion formation, but the latter was not significant. Mortality rates in placebo-treated animals was 37%, 6.25% resveratrol-treated animals was 40%, 12.5% resveratrol-treated animals was 24%, and 19% resveratrol-treated animals was 3%. Collectively, these results demonstrate that resveratrol cream inhibits or reduces HSV replication in the vagina of mice and limits extravaginal disease. Identifier An unambiguous reference to the resource within a given context <a href="http://doi.org/10.1016/j.antiviral.2005.06.008" target="_blank" rel="noreferrer noopener">10.1016/j.antiviral.2005.06.008</a> Rights Information about rights held in and over the resource Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s). 2005 Animals Antiviral Agents/administration & dosage/pharmacology/*therapeutic use Antiviral research Booth Tristan Docherty John J Drug Evaluation Faith Seth A Female Fu Ming Ming Hah Jennifer M Herpes Genitalis/*drug therapy/pathology/virology Herpesvirus 1 Herpesvirus 2 Human/*drug effects/physiology Human/drug effects/isolation & purification/physiology Mice Placebos Preclinical Resveratrol Stilbenes/administration & dosage/pharmacology/*therapeutic use Survival Analysis Sweet Thomas J Vaginal Diseases/*drug therapy/virology Viral Plaque Assay Virus Replication/drug effects Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. URL Address <a href="http://doi.org/10.1002/jor.23262" target="_blank" rel="noreferrer noopener">http://doi.org/10.1002/jor.23262</a> Pages 311–320 Issue 2 Volume 35 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Harpagoside suppresses IL-6 expression in primary human osteoarthritis chondrocytes. Publisher An entity responsible for making the resource available Journal of orthopaedic research : official publication of the Orthopaedic Research Society Date A point or period of time associated with an event in the lifecycle of the resource 2017 2017-02 Subject The topic of the resource *c-FOS/AP-1; *harpagoside; *IL-6; *MMP-13; *osteoarthritis; CCAAT-Enhancer-Binding Protein-beta/metabolism; Chemokines/metabolism; Chondrocytes/*drug effects/metabolism; Drug Evaluation; Glycosides/pharmacology/*therapeutic use; Harpagophytum; Humans; Interleukin-1beta; Interleukin-6/antagonists & inhibitors/*metabolism; Matrix Metalloproteinase 13/metabolism; NF-kappa B/metabolism; Osteoarthritis/*drug therapy/metabolism; Phytotherapy; Plant Extracts/pharmacology/therapeutic use; Preclinical; Primary Cell Culture; Proto-Oncogene Proteins c-fos/metabolism; Pyrans/pharmacology/*therapeutic use; Reactive Oxygen Species/metabolism; Transcription Factor AP-1/metabolism Creator An entity primarily responsible for making the resource Haseeb Abdul; Ansari Mohammad Yunus; Haqqi Tariq M Description An account of the resource There is growing evidence in support of the involvement of inflammatory response in the pathogenesis of osteoarthritis (OA). Harpagoside, one of the bioactive components of Harpagophytum procumbens (Hp), has been shown to possess anti-inflammatory properties. Here we used an in vitro model of inflammation in OA to investigate the potential of harpagoside to suppress the production of inflammatory cytokines/chemokines such as IL-6 and matrix degrading proteases. We further investigated the likely targets of harpagoside in primary human OA chondrocytes. OA chondrocytes were pre-treated with harpagoside before stimulation with IL-1beta. mRNA expression profile of 92 cytokines/chemokines was determined using TaqMan Human Chemokine PCR Array. Expression levels of selected mRNAs were confirmed using TaqMan assays. Protein levels of IL-6 and MMP-13 were assayed by ELISA and immunoblotting. Total protein levels and phosphorylation of signaling proteins were determined by immunoblotting. Cellular localization of Identifier An unambiguous reference to the resource within a given context <a href="http://doi.org/10.1002/jor.23262" target="_blank" rel="noreferrer noopener">10.1002/jor.23262</a> Rights Information about rights held in and over the resource Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s). *c-FOS/AP-1 *harpagoside *IL-6 *MMP-13 *OSTEOARTHRITIS 2017 Ansari Mohammad Yunus CCAAT-Enhancer-Binding Protein-beta/metabolism Chemokines/metabolism Chondrocytes/*drug effects/metabolism Department of Anatomy & Neurobiology Drug Evaluation Glycosides/pharmacology/*therapeutic use Haqqi Tariq M Harpagophytum Haseeb Abdul Humans Interleukin-1beta Interleukin-6/antagonists & inhibitors/*metabolism Journal of orthopaedic research : official publication of the Orthopaedic Research Society Matrix Metalloproteinase 13/metabolism NEOMED College of Medicine NF-kappa B/metabolism Osteoarthritis/*drug therapy/metabolism Phytotherapy Plant Extracts/pharmacology/therapeutic use Preclinical Primary Cell Culture Proto-Oncogene Proteins c-fos/metabolism Pyrans/pharmacology/*therapeutic use Reactive Oxygen Species/metabolism Transcription Factor AP-1/metabolism